2025
SJR Q1
JCR Q3 · 1,9
5 eşleşen makale
SCIE
Dergi ayrıntısı
Contemporary Clinical Trials
- Yayıncı
- Elsevier Inc.
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
1551714415592030
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,966
- Quartile Q1
- H-Index 84
- Atıf/yayın 2,13
- Doküman (3y) 794
- Atıf (3y) 1.847
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 1,9
- 5Y JIF 2,3
- JCI 0,51
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Medicine (miscellaneous) Q1
- Pharmacology (medical) Q1
Alanlar
- Medicine
WoS kategorileri
- Medicine, Research & Experimental | Pharmacology & Pharmacy
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q3 | 0,966 | 1,9 | 2,3 | 0,51 | Q3 | 84 |
| 2024 | Q1 | Q3 | 1,005 | 1,9 | 2,1 | 0,55 | Q3 | 79 |
| 2023 | Q1 | Q3 | 0,98 | 2 | 2,1 | 0,58 | Q3 | 79 |
| 2022 | Q1 | Q3 | 0,847 | 2,2 | 2,2 | 0,58 | Q3 | 79 |
| 2021 | Q1 | Q4 | 0,867 | 2,3 | 2,5 | 0,61 | Q3 | 79 |
| 2020 | Q1 | Q4 | 1,067 | 2,2 | 2,9 | 0,66 | Q3 | 79 |
| 2019 | Q1 | Q3 | 1,051 | 1,8 | 2,5 | 0,8 | Q2 | 79 |
| 2018 | — | Q3 | — | 2,3 | 2,7 | 0,95 | Q2 | — |
| 2017 | Q1 | Q2 | 1,536 | 2,7 | 2,6 | 0,97 | Q2 | 79 |
| 2016 | Q1 | Q3 | 1,266 | 2,1 | 2,1 | — | — | 79 |
| 2015 | Q1 | Q3 | 1,249 | 2,1 | 2 | — | — | 79 |
| 2014 | Q1 | Q3 | 1,222 | 1,9 | 1,9 | — | — | 79 |
| 2013 | Q1 | Q3 | 1,216 | 2 | 1,9 | — | — | 79 |
| 2012 | Q1 | Q3 | 1,18 | 1,6 | 1,9 | — | — | 79 |
| 2011 | Q1 | Q3 | 1,146 | 1,8 | 1,9 | — | — | 79 |
| 2010 | Q1 | Q3 | 1,214 | 1,7 | 2 | — | — | 79 |
| 2009 | — | Q3 | — | 1,5 | 2 | — | — | — |
| 2008 | — | Q3 | — | 1,4 | 1,8 | — | — | — |
| 2007 | — | Q3 | — | 1,4 | 1,4 | — | — | — |
| 2006 | — | Q3 | — | 1,3 | — | — | — | — |
| 2005 | — | — | — | — | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q3 | 129/191 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 253/356 |
| 2024 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q3 | 132/195 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 238/352 |
| 2023 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q3 | 122/189 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 222/354 |
| 2022 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 106/136 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 208/278 |
| 2021 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 119/139 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 220/279 |
| 2020 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 110/140 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 213/276 |
| 2019 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q2 | 103/139 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q2 | 209/271 |
| 2018 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q2 | 80/136 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 157/267 |
| 2017 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q2 | 69/133 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 121/261 |
| 2016 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 76/128 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 156/257 |
| 2015 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 75/124 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 150/255 |
| 2014 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 76/123 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 153/255 |
| 2013 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 72/124 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 150/256 |
| 2012 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 79/121 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 172/261 |
| 2011 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 68/112 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 154/261 |
| 2010 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 61/106 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 161/252 |
| 2009 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 62/93 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 164/237 |
| 2008 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 58/83 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 157/219 |
| 2007 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 52/81 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 139/205 |
| 2006 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 49/76 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 140/199 |
| 2005 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | — | — | — |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | — | — | — |